Studying the effect of hyperoside on recovery from cyclophosphamide induced oligoasthenozoospermia.

IF 2.1 4区 医学 Q3 ANDROLOGY
Qigang Fan, Ruifen He, Yi Li, Pu Gao, Runchun Huang, Rong Li, Jiayu Zhang, Hongli Li, Xiaolei Liang
{"title":"Studying the effect of hyperoside on recovery from cyclophosphamide induced oligoasthenozoospermia.","authors":"Qigang Fan,&nbsp;Ruifen He,&nbsp;Yi Li,&nbsp;Pu Gao,&nbsp;Runchun Huang,&nbsp;Rong Li,&nbsp;Jiayu Zhang,&nbsp;Hongli Li,&nbsp;Xiaolei Liang","doi":"10.1080/19396368.2023.2241600","DOIUrl":null,"url":null,"abstract":"<p><p>Oligoasthenozoospermia is becoming a serious problem, but effective prevention or treatment is lacking. Hyperoside, one of the main active ingredients in traditional Chinese medicine, may be effective in the treatment of oligoasthenozoospermia. In this study, we used cyclophosphamide (CTX: 50 mg/kg) to establish a mouse model of Oligoasthenozoospermia to investigate the therapeutic effect of hyperoside (30 mg/kg) on CTX-induced oligoasthenozoospermia. All mice were divided into four groups: blank control group (Control), treatment control group (Hyp), disease group (CTX) and treatment group (CTX + H). Mice body weight, testicular weight, sperm parameters and testicular histology were used to assess the reproductive capacity of mice and to explore the underlying mechanism of hyperoside in the treatment of oligoasthenozoospermia by assessing hormone levels, protein levels of molecules related to hormone synthesis and transcript levels of important genes related to spermatogenesis. Treatment with hyperoside significantly improved sperm density, sperm viability and testicular function compared to untreated oligoasthenozoospermia mice. In mechanism, treatment with hyperoside resulted in significant improvement in pathological changes in spermatogenic tubules, with an increase in testosterone production, and upregulations of Protein Kinase CAMP-Activated Catalytic Subunit Beta (PRKACB), Steroidogenic Acute Regulatory Protein (STAR), and Cytochrome P450 Family 17 Subfamily A Member 1 (CYP17A1) for testosterone production. Hyperoside also promoted the cell cycle of germ cells and up-regulated meiosis and spermatogenesis-related genes, including DNA Meiotic Recombinase 1 (Dmc1), Ataxia telangiectasia mutated (Atm) and RAD21 Cohesin Complex Component (Rad21). In conclusion, hyperoside exerted protective effects on oligoasthenozoospermia mice by regulating testosterone production, meiosis and sperm maturation of germ cells.</p>","PeriodicalId":22184,"journal":{"name":"Systems Biology in Reproductive Medicine","volume":" ","pages":"333-346"},"PeriodicalIF":2.1000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Systems Biology in Reproductive Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19396368.2023.2241600","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ANDROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Oligoasthenozoospermia is becoming a serious problem, but effective prevention or treatment is lacking. Hyperoside, one of the main active ingredients in traditional Chinese medicine, may be effective in the treatment of oligoasthenozoospermia. In this study, we used cyclophosphamide (CTX: 50 mg/kg) to establish a mouse model of Oligoasthenozoospermia to investigate the therapeutic effect of hyperoside (30 mg/kg) on CTX-induced oligoasthenozoospermia. All mice were divided into four groups: blank control group (Control), treatment control group (Hyp), disease group (CTX) and treatment group (CTX + H). Mice body weight, testicular weight, sperm parameters and testicular histology were used to assess the reproductive capacity of mice and to explore the underlying mechanism of hyperoside in the treatment of oligoasthenozoospermia by assessing hormone levels, protein levels of molecules related to hormone synthesis and transcript levels of important genes related to spermatogenesis. Treatment with hyperoside significantly improved sperm density, sperm viability and testicular function compared to untreated oligoasthenozoospermia mice. In mechanism, treatment with hyperoside resulted in significant improvement in pathological changes in spermatogenic tubules, with an increase in testosterone production, and upregulations of Protein Kinase CAMP-Activated Catalytic Subunit Beta (PRKACB), Steroidogenic Acute Regulatory Protein (STAR), and Cytochrome P450 Family 17 Subfamily A Member 1 (CYP17A1) for testosterone production. Hyperoside also promoted the cell cycle of germ cells and up-regulated meiosis and spermatogenesis-related genes, including DNA Meiotic Recombinase 1 (Dmc1), Ataxia telangiectasia mutated (Atm) and RAD21 Cohesin Complex Component (Rad21). In conclusion, hyperoside exerted protective effects on oligoasthenozoospermia mice by regulating testosterone production, meiosis and sperm maturation of germ cells.

研究金丝桃苷对环磷酰胺诱导的少弱精子症恢复的影响。
少弱精子症已成为一个严重的问题,但缺乏有效的预防或治疗。金丝桃苷是中药中的主要活性成分之一,可有效治疗少弱精子症。在本研究中,我们使用环磷酰胺(CTX:50 mg/kg)建立小鼠弱精子症模型,观察金丝桃苷(30 mg/kg)对CTX诱导的少弱精子症的作用。将所有小鼠分为四组:空白对照组(对照组)、治疗对照组(Hyp)、疾病组(CTX)和治疗组(CT + H) 。通过评估激素水平、激素合成相关分子的蛋白质水平和精子发生相关重要基因的转录水平,利用小鼠体重、睾丸重量、精子参数和睾丸组织学来评估小鼠的生殖能力,并探索金丝桃苷治疗少弱精子症的潜在机制。与未经治疗的少弱精子症小鼠相比,金丝桃苷治疗显著改善了精子密度、精子活力和睾丸功能。在机制上,金丝桃苷治疗显著改善了生精小管的病理变化,增加了睾酮的产生,并上调了蛋白激酶CAMP激活的催化亚基β(PRKACB)、类固醇生成急性调节蛋白(STAR)和细胞色素P450家族17亚家族A成员1(CYP17A1)的睾酮产生。金丝桃苷还促进生殖细胞的细胞周期,并上调减数分裂和精子发生相关基因,包括DNA减数分裂重组酶1(Dmc1)、共济失调毛细血管扩张突变(Atm)和RAD21内聚蛋白复合成分(RAD21)。综上所述,金丝桃苷通过调节生殖细胞的睾酮生成、减数分裂和精子成熟,对少弱精子症小鼠具有保护作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.30
自引率
4.20%
发文量
27
审稿时长
>12 weeks
期刊介绍: Systems Biology in Reproductive Medicine, SBiRM, publishes Research Articles, Communications, Applications Notes that include protocols a Clinical Corner that includes case reports, Review Articles and Hypotheses and Letters to the Editor on human and animal reproduction. The journal will highlight the use of systems approaches including genomic, cellular, proteomic, metabolomic, bioinformatic, molecular, and biochemical, to address fundamental questions in reproductive biology, reproductive medicine, and translational research. The journal publishes research involving human and animal gametes, stem cells, developmental biology and toxicology, and clinical care in reproductive medicine. Specific areas of interest to the journal include: male factor infertility and germ cell biology, reproductive technologies (gamete micro-manipulation and cryopreservation, in vitro fertilization/embryo transfer (IVF/ET) and contraception. Research that is directed towards developing new or enhanced technologies for clinical medicine or scientific research in reproduction is of significant interest to the journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信